TVRD
Tvardi Therapeutics, Inc.
Next earnings Aug 12, 2026 · consensus $-0.71 EPS
Last earnings -0.7% on 2026-05-08
$1.50
▼ -36.44%$1.50▼ -94.09%
over 1Y
L $1.50EODHDH $42.98
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-36.4%
1W-44.0%
1M-54.5%
3M-52.7%
YTD-63.2%
1Y-94.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity 0.53x); but revenue fell -66.0% YoY.
Revenue (FY2024) $7.14M · FY2024
Tvardi Therapeutics, Inc. shows $7.14M in FY2024 revenue (-66.0% YoY), a -255.2% net margin, and -87.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $23.0M | $41.9M | $21.0M | $7.14M | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$89.1M | -$87.5M | -$121M | -$28.1M | -$26.7M |
| Net income | -$88.4M | -$85.5M | -$119M | -$29.4M | -$18.2M |
| Diluted EPS | -$1.74 | -$19.12 | -$26.26 | -$11.42 | -$3.26 |
| Net margin | -384.1% | -204.2% | -565.2% | -411.9% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$6.66M
EV / EBITDA—
EV / Sales-0.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-129.4%
FCF yield-174.4%
Quality & risk
ROIC (est.)-100.9%
Free cash flow-$24.5M
Total debt—
Net cash$20.7M
Altman Z-Score-5.83 distress
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+105.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗8-KPeriod ending 2026-06-092026-06-11open ↗EFFECTFiling2026-05-13open ↗EFFECTFiling2026-05-12open ↗POS AMFiling2026-05-08open ↗10-QPeriod ending 2026-03-312026-05-08open ↗8-KPeriod ending 2026-05-082026-05-08open ↗S-3Filing2026-05-01open ↗
Frequently asked
- Is Tvardi Therapeutics, Inc. (TVRD) a buy?
- TVRD currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.53x); but revenue fell -66.0% YoY.
- What is Tvardi Therapeutics, Inc.'s quality score?
- TVRD scores 54.09803921568628/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001346830, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 8:38:29 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.